New bis-N9-(methylphenylmethyl)purine derivatives: Synthesis and antitumor activity

European Journal of Medicinal Chemistry

Volumn 42, Issue 3, 2007, Pages 327-333

  Kode, Nageswara ^a   Chen, Liying ^a   Murthy, Devangachinta ^a   Adewumi, Dare ^a   Phadtare, Shashikant ^a  

^a XAVIER UNIVERSITY OF LOUISIANA   (United States)

Author keywords

Antitumor activity; Bis 9 (methylphenylmethyl)chloropurines; Bisarylpurines

Indexed keywords

BIS 9 [2 (METHYLPHENYLMETHYL)] 2,6 DICHLOROPURINE; BIS 9 [2 (METHYLPHENYLMETHYL)] 6 CHLOROPURINE; BIS 9 [2 (METHYLPHENYLMETHYL)]ADENINE; BIS 9 [3 (METHYLPHENYLMETHYL)] 2,6 DICHLOROPURINE; BIS 9 [3 (METHYLPHENYLMETHYL)] 6 CHLOROPURINE; BIS 9 [3 (METHYLPHENYLMETHYL)]ADENINE; BIS 9 [4 (METHYLPHENYLMETHYL)] 2,6 DICHLOROPURINE; BIS 9 [4 (METHYLPHENYLMETHYL)] 6 CHLOROPURINE; BIS 9 [4 (METHYLPHENYLMETHYL)]ADENINE; BIS 9 [4,4' BIS(METHYL) 1,1' BIPHENYL] 2,6 DICHLOROPURINE; BIS 9 [4,4' BIS(METHYL) 1,1' BIPHENYL] 6 CHLOROPURINE; BIS 9 [4,4' BIS(METHYL) 1,1' BIPHENYL]ADENINE; PURINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CENTRAL NERVOUS SYSTEM TUMOR; COLON CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG POTENCY; DRUG SYNTHESIS; HEALTH CARE ORGANIZATION; HUMAN; HUMAN CELL; KIDNEY CANCER; LEUKEMIA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; PROSTATE CANCER; SENSITIVITY ANALYSIS;

ALKYLATION; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATOGRAPHY, THIN LAYER; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; PURINES; SPECTROPHOTOMETRY, ULTRAVIOLET; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33847384986     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2006.10.017     Document Type: Article

References (14)

1. Schwartsmann G., Ratain M.J., Cragg G.M., Wong J.E., Saijo N., Parkinson D.R., Fujiwara Y., Pazdur R., Newman D.J., Dagher R., and DiLeone L. J. Clin. Oncol. 20 (2002) 47-59
2. Gregson S., Howard P., Gullick D., Hamaguchi A., Corcoran K., Brooks N., Hartley J., Jenkins T., Patel S., and Guille M. J. Med. Chem. 47 (2004) 1161-1174
3. Bischoff P.L., Holl V., Coelho D., Dufour P., Weltin D., and Luu B. Curr. Med. Chem. 7 (2000) 693-713
4. Mann J., Baron A., Opoku-Boahen Y., Johansson E., Parkinson G., Kelland L.R., and Neidle S. J. Med. Chem. 44 (2001) 138-144
5. Gregson S., Howard P., Hartley J., Brooks N., Adams L., Jenkins T., Kelland L., and Thurston D. J. Med. Chem. 44 (2001) 737-748
6. Brakta M., Murthy D., Ellis L., and Phadtare S. Bioorg. Med. Chem. Lett. 12 (2002) 1489-1492
7. Murthy D., Brakta M., Ellis L., Abanah O., and Phadtare S. Med. Chem. Res. 12 (2003) 13-25
8. Phadtare S., Kessel D., Corbett T.H., Renis H.E., Court B.A., and Zemlicka J. J. Med. Chem. 34 (1991) 421-429
9. Grever M.R., Schepartz S.A., and Chabner B.A. Semin. Oncol. 19 (1992) 622-638
10. Boyd M.R., and Paul K.D. Drug Dev. Res. 34 (1995) 91
11. Skehan P., Storeng R., and Scudiero D. J. Natl. Cancer Inst. 82 (1990) 1107-1112
12. Boyd M.R., Shomaker R.H., and McLemore T.L. New drug development. In: Roth J.A., Ruckdeschel J.C., and Weisenburger T.H. (Eds). Thoracic Oncology (1989), Saunders, Philadelphia 711-721
13. Gray G.D., and Wickstorm E. BioTechniques 21 (1996) 780-782
14. Monks A., Scudiero D., Skehan P., Showmaker R., Paull K., Vistica D., Hose C., Langley J., Cronise P., Vaigro-Wolf A., Gray-Goodrich M., Campbell H., Mayo J., and Boyd M. J. Natl. Cancer Inst. 83 (1991) 757-766